ES2565190T3 - Reducción de mareos, un efecto secundario asociado a la terapia de pirfenidona - Google Patents

Reducción de mareos, un efecto secundario asociado a la terapia de pirfenidona Download PDF

Info

Publication number
ES2565190T3
ES2565190T3 ES10075728.5T ES10075728T ES2565190T3 ES 2565190 T3 ES2565190 T3 ES 2565190T3 ES 10075728 T ES10075728 T ES 10075728T ES 2565190 T3 ES2565190 T3 ES 2565190T3
Authority
ES
Spain
Prior art keywords
reduced
probability
pirfenidone
pirfenidone therapy
dizziness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10075728.5T
Other languages
English (en)
Spanish (es)
Inventor
Cynthia Y. Robinson
Jeffery Stuart Loutit
Michelle M. Freemer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2565190(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Application granted granted Critical
Publication of ES2565190T3 publication Critical patent/ES2565190T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
ES10075728.5T 2005-12-02 2006-11-29 Reducción de mareos, un efecto secundario asociado a la terapia de pirfenidona Active ES2565190T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74197605P 2005-12-02 2005-12-02
US741976P 2005-12-02

Publications (1)

Publication Number Publication Date
ES2565190T3 true ES2565190T3 (es) 2016-04-01

Family

ID=37807840

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10075728.5T Active ES2565190T3 (es) 2005-12-02 2006-11-29 Reducción de mareos, un efecto secundario asociado a la terapia de pirfenidona
ES06838621T Active ES2385935T3 (es) 2005-12-02 2006-11-29 Reducción de mareos, un efecto secundario asociado con la terapia de pirfenidona.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06838621T Active ES2385935T3 (es) 2005-12-02 2006-11-29 Reducción de mareos, un efecto secundario asociado con la terapia de pirfenidona.

Country Status (13)

Country Link
US (1) US20070203202A1 (enExample)
EP (2) EP1965797B1 (enExample)
JP (3) JP5175740B2 (enExample)
AT (1) ATE497766T1 (enExample)
CA (1) CA2631646C (enExample)
CY (1) CY1111355T1 (enExample)
DE (1) DE602006020070D1 (enExample)
DK (1) DK1965797T3 (enExample)
ES (2) ES2565190T3 (enExample)
PL (1) PL1965797T3 (enExample)
PT (1) PT1965797E (enExample)
SI (1) SI1965797T1 (enExample)
WO (1) WO2007064738A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
JP2010513320A (ja) * 2006-12-18 2010-04-30 インターミューン インコーポレイテッド ピルフェニドン治療を患者に提供する方法
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
CA2691379C (en) 2007-06-20 2015-06-09 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
ES2913095T3 (es) 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
CN103561741A (zh) * 2011-03-08 2014-02-05 奥斯拜客斯制药有限公司 取代的n-芳基吡啶酮
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
KR102045723B1 (ko) * 2011-09-14 2019-11-18 시오노기 앤드 컴파니, 리미티드 흡입용 의약 조성물
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
EP2968292A4 (en) 2013-03-15 2016-11-23 Intermune Inc METHOD FOR IMPROVING MICROVASCULAR INTEGRITY
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
WO2021107060A1 (ja) * 2019-11-27 2021-06-03 塩野義製薬株式会社 ピルフェニドンの副作用を軽減するための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
WO2004110245A2 (en) * 2003-05-16 2004-12-23 Intermune, Inc. Combination therapy for cancer treatment
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy

Also Published As

Publication number Publication date
ES2385935T3 (es) 2012-08-03
EP1965797B1 (en) 2011-02-09
JP5175740B2 (ja) 2013-04-03
US20070203202A1 (en) 2007-08-30
HK1151726A1 (en) 2012-02-10
EP2316453B1 (en) 2016-01-06
SI1965797T1 (sl) 2011-03-31
JP2012229275A (ja) 2012-11-22
PL1965797T3 (pl) 2011-07-29
ATE497766T1 (de) 2011-02-15
CA2631646C (en) 2016-07-26
HK1123213A1 (en) 2009-06-12
EP1965797A1 (en) 2008-09-10
CY1111355T1 (el) 2015-08-05
CA2631646A1 (en) 2007-06-07
WO2007064738A1 (en) 2007-06-07
DE602006020070D1 (de) 2011-03-24
JP2009518293A (ja) 2009-05-07
PT1965797E (pt) 2011-05-12
JP2015061888A (ja) 2015-04-02
DK1965797T3 (da) 2011-05-02
EP2316453A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
JP7670700B2 (ja) 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
RU2356547C2 (ru) Способы лечения рака с использованием ингибиторов hdac
ES2935605T3 (es) Combinaciones de cannabinoides y N-aciletanolaminas
ES2450615T3 (es) Composiciones que comprenden Tramadol y Celecoxib para el tratamiento del dolor
ES3018234T3 (en) Fluralaner for use in the treatment of demodicosis
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
ES2617252T3 (es) Solución oral que comprende clorhidrato de atomoxetina
JP2005529896A5 (enExample)
AR053680A1 (es) Composicion
ES2648225T3 (es) Combinaciones sinérgicas de antagonistas de VR-1 e inhibidores de COX-2
ES2385935T3 (es) Reducción de mareos, un efecto secundario asociado con la terapia de pirfenidona.
BRPI0510449A (pt) uso de formulações de meloxicam em medicina veterinária
RU2016137926A (ru) Композиции грапипранта и способы их применения
BRPI0517719A (pt) composição veterinária transmucosal compreendendo detomidina
ES2950492T3 (es) Nalmefeno para la reducción del consumo de alcohol en poblaciones objetivos específicas
ES3055714T3 (en) Modified release pharmaceutical compositions of huperzine
ES2635421T3 (es) Composiciones farmacéuticas que comprenden (S)-(+)-7-(1H-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para tratar enfermedades y trastornos cutáneos
WO2007054348A1 (de) Neue arzneimittel
Laturkar et al. Overview on doxycycline-and its adverse reactions
ES2688577T3 (es) Composiciones de buprenorfina en dosis altas y uso como analgésico
AU2024201396A1 (en) Compositions and methods for the treatment of skin lesions
ES2698403T3 (es) Composición farmacéutica inyectable estable de agonista de receptor de vitamina D y proceso para su preparación
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
CO6241114A2 (es) Composicion farmaceutica que comprende la combinacion del agente antimicrobiano ciprofloxacino y el agente antioxidante acido ascorbico para el tratamiento de infecciones urinarias
Campos et al. Evaluation of the local analgesic effects of a commercial aqueous extract of Sarracenia purpurea and ammonium sulfate in the equine abaxial sesamoid block model